CalcMyPeptide
GH Secretagogues

CJC-1295 With DAC vs Without DAC: Half-Life, Dosing Frequency & Which to Choose

CJC-1295 with DAC provides sustained GH elevation for days while CJC-1295 without DAC (Mod GRF 1-29) creates physiological pulses. Complete comparison with dosing protocols.

11 min read
Table of Contents

⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.

The Pharmacokinetic Divide: CJC-1295 DAC vs. No DAC

In the landscape of Growth Hormone Releasing Hormone (GHRH) analogues, the distinction between CJC-1295 with DAC and CJC-1295 No DAC (often confusingly sold as Mod GRF 1-29) represents one of the most critical structural and clinical bifurcations. Understanding the DAC modification is mandatory for constructing a safe and effective GH secretagogue protocol.

Both compounds are synthetic, tetrasubstituted analogues of the first 29 amino acids of endogenous GHRH. Their primary function is identical: they bind to GHRH receptors on the anterior pituitary to stimulate the synthesis and release of Growth Hormone (GH).

However, their pharmacokinetic behavior—specifically their half-life and the resulting pattern of GH release—could not be more different. This divergence dictates their respective clinical applications, dosing schedules, and side effect profiles.

What is the DAC Modification?

DAC stands for Drug Affinity Complex. It is a crucial biochemical modification wherein a reactive maleimidopropionic acid (MPA) group is attached to the peptide chain.

The Albumin Binding Mechanism: Upon injection, the MPA group immediately and covalently binds to endogenous serum albumin in the bloodstream.

Biochemical Shielding: Because serum albumin is a massive, long-lasting transport protein, the bound CJC-1295 is shielded from enzymatic degradation (specifically by DPP-4) and renal clearance.

The Half-Life Extension: While native GHRH has a half-life measured in minutes, the DAC modification extends the functional half-life of CJC-1295 to approximately 5 to 8 days. This is a monumental pharmacokinetic shift.

Pharmacokinetic half-life chart of CJC-1295 DAC versus modified GRF 1-29 (No DAC).
The DAC (Drug Affinity Complex) binds to albumin, extending the half-life to 8 days but eliminating physiological GH pulsatility (a "GH bleed"). CJC-1295 No DAC (30-min half-life) maintains the natural pulsatile rhythm.

CJC-1295 No DAC (Mod GRF 1-29): Physiological Pulsatility

CJC-1295 No DAC lacks the maleimidopropionic acid group. Biologically, it is essentially modified GRF 1-29 (tetrasubstituted to resist rapid cleavage), giving it a half-life of roughly 30 minutes.

Physiological Mimicry: Because of its short half-life, an injection of No DAC induces an immediate, sharp, and transient spike in Growth Hormone release that closely mimics a healthy, natural GH pulse.

Receptor Recovery: By rapidly clearing from the system, it allows the pituitary GHRH receptors to reset. This preserves insulin sensitivity and avoids downregulation (desensitization) of the receptors.

Clinical Application: It is widely considered the superior choice for long-term anti-aging, fat loss, and recovery protocols. However, it requires multiple daily injections (often stacked with Ipamorelin) to achieve maximum benefit.

CJC-1295 with DAC: Continuous GH Bleed

Because the DAC version remains active in the bloodstream for over a week, it continually agonizes the pituitary GHRH receptors, resulting in what endocrinologists refer to as a GH bleed.

The Benefit: It requires highly infrequent injections (typically once or twice a week) while maintaining consistently elevated baseline levels of GH and IGF-1.

The Risk Profile: The human body is entirely unaccustomed to continuous, non-pulsatile GH elevation. This sustained receptor activation mimics the pathological state of acromegaly or exogenous GH abuse more closely than physiological optimization.

Adverse Consequences: The continuous "bleed" frequently leads to rapid receptor desensitization, severe water retention, joint pain (arthralgia), and clinically significant insulin resistance resulting in elevated fasting blood glucose.

Which Version Should You Choose?

For the overwhelming majority of clinical anti-aging, body composition, and regenerative medicine protocols, CJC-1295 No DAC is the definitive standard.

No DAC preserves the vital pulsatile nature of GH release, safeguarding insulin sensitivity and preventing pituitary burnout. It is the preferred partner for stacking with a GHRP like Ipamorelin.

With DAC offers extreme convenience but carries a substantially heavier burden of adverse metabolic side effects. Its use is generally reserved for highly advanced, short-term research contexts where a constant elevation in IGF-1 is prioritized over physiological homeostasis.

Final Word

⚕️ Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.

Frequently Asked Questions

Is Mod GRF 1-29 the exact same thing as CJC-1295 No DAC?
Scientifically, CJC-1295 No DAC is a misnomer; the compound is actually Modified GRF 1-29. However, because early peptide vendors marketed Mod GRF 1-29 as "CJC-1295 without DAC," the industry adopted the technically incorrect name. Functionally, they refer to the exact same 29-amino acid tetrasubstituted peptide.
Does CJC-1295 with DAC cause more water retention than No DAC?
Yes. The DAC modification causes a continuous, non-pulsatile elevation of circulating GH and IGF-1 (a "GH bleed"). This sustained elevation heavily promotes sodium and water retention, leading to significant edema (swelling) and related joint pain in a large percentage of users compared to the pulsatile No DAC version.
Why is CJC-1295 No DAC almost always stacked with Ipamorelin?
They operate via synergistic, non-competing pathways. CJC-1295 No DAC (a GHRH) signals the pituitary to produce GH, while Ipamorelin (a GHRP) signals the pituitary to release the stored GH. Using them together produces a GH spike that is exponentially larger than using either compound individually.
How often do you need to inject CJC-1295 with DAC vs No DAC?
Due to its ~8-day half-life, CJC-1295 with DAC is typically administered only 1 to 2 times per week. CJC-1295 No DAC, with its ~30-minute half-life, is rapidly cleared and must be administered 1 to 3 times per day to achieve a cumulative clinical effect.

🧪 Try the Calculator

Put this knowledge into practice — calculate your exact concentration and syringe units for free.

Open Reconstitution Calculator →

📋 Featured In Clinical Protocols

Related Articles

Share this article

Found this useful? Let others know too.